company background image
PLXP

PLx PharmaNasdaqCM:PLXP Stock Report

Market Cap

US$282.8m

7D

2.0%

1Y

80.2%

Updated

26 Nov, 2021

Data

Company Financials +
PLXP fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

PLXP Stock Overview

PLx Pharma Inc., a specialty pharmaceutical company, focuses on developing the PLxGuard drug delivery system to provide various products in the United States.

Price History & Performance

Summary of all time highs, changes and price drops for PLx Pharma
Historical stock prices
Current Share PriceUS$10.27
52 Week HighUS$21.50
52 Week LowUS$5.01
Beta4.56
1 Month Change-12.89%
3 Month Change-42.79%
1 Year Change80.18%
3 Year Change149.88%
5 Year Changen/a
Change since IPO18.05%

Recent News & Updates

Nov 03
Most Shareholders Will Probably Find That The CEO Compensation For PLx Pharma Inc. (NASDAQ:PLXP) Is Reasonable

Most Shareholders Will Probably Find That The CEO Compensation For PLx Pharma Inc. (NASDAQ:PLXP) Is Reasonable

Despite strong share price growth of 248% for PLx Pharma Inc. ( NASDAQ:PLXP ) over the last few years, earnings growth...

Sep 23
We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To Grow

We're Interested To See How PLx Pharma (NASDAQ:PLXP) Uses Its Cash Hoard To Grow

Just because a business does not make any money, does not mean that the stock will go down. By way of example, PLx...

Sep 17

PLx Pharma: First Commercial Launch Makes It Attractive

PLx Pharma has just launched its lead product VAZALORE, the first liquid-filled aspirin capsule. The Company’s PLxGuard drug delivery platform has the potential to be used with other approved or under-development drugs and NSAIDs. The Company has a comfortable cash runway to carry through the VAZALORE manufacturing and distribution while advancing the pipeline for existing and prospective candidates.

Shareholder Returns

PLXPUS PharmaceuticalsUS Market
7D2.0%-0.5%-2.7%
1Y80.2%17.7%21.3%

Return vs Industry: PLXP exceeded the US Pharmaceuticals industry which returned 17.7% over the past year.

Return vs Market: PLXP exceeded the US Market which returned 21.3% over the past year.

Price Volatility

Is PLXP's price volatile compared to industry and market?
PLXP volatility
PLXP Average Weekly Movement11.6%
Pharmaceuticals Industry Average Movement9.3%
Market Average Movement5.9%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market2.2%

Stable Share Price: PLXP is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: PLXP's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200210Natasha Giordanohttps://plxpharma.com

PLx Pharma Inc., a specialty pharmaceutical company, focuses on developing the PLxGuard drug delivery system to provide various products in the United States. The company’s lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system, which provides patients with vascular disease and diabetic patients who are candidates for aspirin therapy based on physician recommendation, with fast, reliable, and predictable platelet inhibition as compared to enteric-coated aspirin, as well as reduces the risk of stomach erosions and ulcers as compared with immediate-release aspirin, after seven days of treatment. Its product pipeline also includes other oral nonsteroidal anti-inflammatory drugs using the PLxGuard drug delivery system, such as PL1200 Ibuprofen 200 mg and PL1200 Ibuprofen 400 mg, which are in Phase I clinical stage for pain and inflammation, as well as PL1100 Ibuprofen 400 mg.

PLx Pharma Fundamentals Summary

How do PLx Pharma's earnings and revenue compare to its market cap?
PLXP fundamental statistics
Market CapUS$282.81m
Earnings (TTM)-US$60.70m
Revenue (TTM)US$6.62m

42.7x

P/S Ratio

-4.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PLXP income statement (TTM)
RevenueUS$6.62m
Cost of RevenueUS$3.91m
Gross ProfitUS$2.70m
ExpensesUS$63.41m
Earnings-US$60.70m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.20
Gross Margin40.86%
Net Profit Margin-917.51%
Debt/Equity Ratio0%

How did PLXP perform over the long term?

See historical performance and comparison

Valuation

Is PLx Pharma undervalued compared to its fair value and its price relative to the market?

9.15x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PLXP's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate PLXP's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: PLXP is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: PLXP is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PLXP's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PLXP is overvalued based on its PB Ratio (9.2x) compared to the US Pharmaceuticals industry average (2.7x).


Future Growth

How is PLx Pharma forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

41.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PLXP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PLXP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PLXP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PLXP's revenue (55.9% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: PLXP's revenue (55.9% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PLXP's Return on Equity is forecast to be high in 3 years time


Past Performance

How has PLx Pharma performed over the past 5 years?

-37.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PLXP is currently unprofitable.

Growing Profit Margin: PLXP is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PLXP is unprofitable, and losses have increased over the past 5 years at a rate of 37.4% per year.

Accelerating Growth: Unable to compare PLXP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PLXP is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.2%).


Return on Equity

High ROE: PLXP has a negative Return on Equity (-122.61%), as it is currently unprofitable.


Financial Health

How is PLx Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: PLXP's short term assets ($88.6M) exceed its short term liabilities ($7.4M).

Long Term Liabilities: PLXP's short term assets ($88.6M) exceed its long term liabilities ($37.4M).


Debt to Equity History and Analysis

Debt Level: PLXP is debt free.

Reducing Debt: PLXP currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PLXP has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: PLXP has sufficient cash runway for 2.8 years if free cash flow continues to reduce at historical rates of 27.4% each year.


Dividend

What is PLx Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PLXP's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PLXP's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PLXP's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PLXP's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PLXP's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average management tenure


CEO

Natasha Giordano (61 yo)

5.83yrs

Tenure

US$2,436,578

Compensation

Ms. Natasha Giordano serves as Independent Director at Matinas BioPharma Holdings, Inc. since September 14, 2020. She has been Chief Executive Officer and President at PLx Pharma Inc. since January 1, 2016...


CEO Compensation Analysis

Compensation vs Market: Natasha's total compensation ($USD2.44M) is above average for companies of similar size in the US market ($USD1.10M).

Compensation vs Earnings: Natasha's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PLXP's management team is considered experienced (4.2 years average tenure).


Board Members

Experienced Board: PLXP's board of directors are considered experienced (4.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 200.7%.


Top Shareholders

Company Information

PLx Pharma Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: PLx Pharma Inc.
  • Ticker: PLXP
  • Exchange: NasdaqCM
  • Founded: 2002
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$282.806m
  • Shares outstanding: 27.54m
  • Website: https://plxpharma.com

Number of Employees


Location

  • PLx Pharma Inc.
  • 9 Fishers Lane
  • Suite E
  • Sparta
  • New Jersey
  • 7871
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/26 23:18
End of Day Share Price2021/11/26 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.